NCT03132519View on ClinicalTrials.gov

Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation

PHASE4CompletedINTERVENTIONAL

Enrollment

364

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions

CoughHypertension

Interventions

DRUG

Remifentanil

To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation

Trial Locations (1)

76001000

Fundacion Valle del Lili, Santiago de Cali

All Listed Sponsors

lead

Fundacion Clinica Valle del Lili

OTHER

NCT03132519 - Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation | Biotech Hunter | Biotech Hunter